Treosulfan-Thiotepa-Fludarabine-Based Conditioning Regimen for Allogeneic Transplantation in Patients with Thalassemia Major: A Single-Center Experience from North India

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 492-495

  Choudhary, Dharma ^a   Sharma, Sanjeev Kumar ^a   Gupta, Nitin ^a   Kharya, Gaurav ^a   Pavecha, Punita ^a   Handoo, Anil ^a   Setia, Rasika ^a   Katewa, Satyendra ^b  

^a BLK Super Speciality Hospital   (India)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Conditioning regimens; Graft versus host disease; Hematopoietic stem cell transplantation; Treatment related mortality; Veno occlusive disease

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONDITIONING; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIA; MALE; MORTALITY; PRESCHOOL CHILD; SCHOOL CHILD; THALASSEMIA MAJOR; TREATMENT DURATION; VEIN OCCLUSION;

ADOLESCENT; BETA-THALASSEMIA; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIA; MALE; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84873710199     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.11.007     Document Type: Article

References (15)

1. Lucarelli G., Galimberti M., Polchi P., et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993, 329:840-844.
2. Galimberti M., Angelucci E., Baroncianni D., et al. Bone marrow transplantation in thalasemia: the experience of Pesaro. Bone Marrow Transplant 1997, 19:45-47.
3. Schrier S.L., Angelucci E. New strategies in the treatment of the thalassemias. Ann Rev Med 2005, 56:157-171.
4. Lucarelli G., Clift R.A., Galimberti M., et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996, 87:2082-2088.
5. Isgrò A., Gaziev J., Sodani P., et al. Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia. Ann NY Acad Sci 2010, 1202:149-154.
6. Gaziev J., Lucarelli G. Hematopoietic stem cell transplantation for thalassemia. Curr Stem Cell Res Ther 2011, 6:162-169.
7. Mathews V., George B., Deotare U., et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with β thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:889-894.
8. Sodani P., Gaziev D., Polchi P., et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004, 104:1201-1203.
9. Gaziev J., Nguyen L., Puozzo C., et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010, 115:4597-4604.
10. Bernardo M.E., Piras E., Vacca A., et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012, 120:473-476.
11. Lucarelli G., Gaziev J. Advances in allogeneic transplantation for thalassemia. Blood Rev 2008, 22:53-63.
12. Sabloff M., Chandy M., Wang Z., et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood 2011, 117:1745-1750.
13. Casper J., Knauf W., Kiefer T., et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic haematopoietic stem cell transplantation. Blood 2004, 103:725-731.
14. Casper J., Wolff D., Knauf W., et al. Allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 2010, 28:3344-3351.
15. Schmidt-Hieber M., Blau I.W., Trenschel R., et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2007, 39:389-396.